1. Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies
- Author
-
Temple, William C, Nix, Matthew A, Naik, Akul, Izgutdina, Adila, Huang, Benjamin J, Wicaksono, Gianina, Phojanakong, Paul, Serrano, Juan Antonio Camara, Young, Elizabeth P, Ramos, Emilio, Salangsang, Fernando, Steri, Veronica, Xirenayi, Simayijiang, Hermiston, Michelle, Logan, Aaron C, Stieglitz, Elliot, and Wiita, Arun P
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Orphan Drug ,Cancer ,Immunization ,Hematology ,Pediatric ,Rare Diseases ,Immunotherapy ,Lymphatic Research ,Pediatric Cancer ,Gene Therapy ,Lymphoma ,Biotechnology ,Genetics ,Childhood Leukemia ,5.1 Pharmaceuticals ,5.2 Cellular and gene therapies ,Animals ,Humans ,Receptors ,Chimeric Antigen ,Immunotherapy ,Adoptive ,T-Lymphocytes ,Camelids ,New World ,Burkitt Lymphoma ,Recurrence ,Antigens ,Differentiation ,B-Lymphocyte ,Antigens ,CD ,Cell Engineering ,Hematologic Neoplasms ,Translational Medical Research ,Oncology and carcinogenesis - Abstract
BackgroundApproximately 50% of patients who receive anti-CD19 CAR-T cells relapse, and new immunotherapeutic targets are urgently needed. We recently described CD72 as a promising target in B-cell malignancies and developed nanobody-based CAR-T cells (nanoCARs) against it. This cellular therapy design is understudied compared with scFv-based CAR-T cells, but has recently become of significant interest given the first regulatory approval of a nanoCAR in multiple myeloma.MethodsWe humanized our previous nanobody framework regions, derived from llama, to generate a series of humanized anti-CD72 nanobodies. These nanobody binders were inserted into second-generation CD72 CAR-T cells and were evaluated against preclinical models of B cell acute lymphoblastic leukemia and B cell non-Hodgkin's lymphoma in vitro and in vivo. Humanized CD72 nanoCARs were compared with parental ("NbD4") CD72 nanoCARs and the clinically approved CD19-directed CAR-T construct tisangenlecleucel. RNA-sequencing, flow cytometry, and cytokine secretion profiling were used to determine differences between the different CAR constructs. We then used affinity maturation on the parental NbD4 construct to generate high affinity binders against CD72 to test if higher affinity to CD72 improved antitumor potency.ResultsToward clinical translation, here we humanize our previous nanobody framework regions, derived from llama, and surprisingly discover a clone ("H24") with enhanced potency against B-cell tumors, including patient-derived samples after CD19 CAR-T relapse. Potentially underpinning improved potency, H24 has moderately higher binding affinity to CD72 compared with a fully llama framework. However, further affinity maturation (KD
- Published
- 2023